TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31793890

Group type: EXPERIMENTAL
Intervention: YouthCHAT
Number of subjects: 129

Group type: COMPARATOR
Intervention: HEEADSSS
Number of subjects: 129
Study: 29368902

Group type: EXPERIMENTAL
Intervention: Calendula officinalis diluted 10% as an irrigant during surgical extraction and mouthwash for a week after extraction.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline solution as an irrigant during surgical extraction and mouthwash for a week after extraction.
Number of subjects: 0
Study: 27118687

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 9270
Study: 25132069

Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y gastric bypass
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal weight control
Number of subjects: 32
Study: 22249475

Group type: EXPERIMENTAL
Intervention: 200,000 IU of retinol every four months
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation for 10 days
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Zinc (40 mg twice weekly)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Both retinol and zinc
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation in apolipoprotein E4(+) children
Number of subjects: 213

Group type: COMPARATOR
Intervention: Apolipoprotein E4(‐) children (regardless of intervention)
Number of subjects: 213
Study: 18484198

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (four cycles of fluorouracil, epirubicin, and cyclophosphamide)
Number of subjects: 698
Study: 17154437

Group type: EXPERIMENTAL
Intervention: Clonazepam test formulation from Ranbaxy Laboratories Ltd (2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivotril from Roche Laboratórios Ltda (2 mg)
Number of subjects: 0
Study: 15688960

Group type: EXPERIMENTAL
Intervention: Daily flossing regime
Number of subjects: 39

Group type: COMPARATOR
Intervention: Manual toothbrush alone
Number of subjects: 39
Study: 12208408

Group type: EXPERIMENTAL
Intervention: Amiodarone (300 mg over 10 minutes)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ibutilide (1 mg over 5 minutes)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Amiodarone (after crossover)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ibutilide (after crossover)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Amiodarone and/or Ibutilide
Number of subjects: 25
Study: 9803987

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg) with ferrous sulphate (300 mg)
Number of subjects: 7
Study: 7648804

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2930250

Group type: EXPERIMENTAL
Intervention: 100 ppm carbon monoxide (CO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 200 ppm carbon monoxide (CO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 10
Study: 105825

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: ICI 74,917
Number of subjects: 32
Study: 30678165

Group type: EXPERIMENTAL
Intervention: Model 1 (age, weight, height, BMI)
Number of subjects: 2225

Group type: EXPERIMENTAL
Intervention: Model 2 (raw BIA variables: bioimpedance-index and phase angle)
Number of subjects: 2225

Group type: EXPERIMENTAL
Intervention: Equations developed for BMI categories
Number of subjects: 2225
Study: 27927884

Group type: EXPERIMENTAL
Intervention: Prefabricated zirconia abutment with pressed ceramic (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CAD/CAM zirconia abutment with hand buildup technique (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 26469515

Group type: EXPERIMENTAL
Intervention: High protein diet (humans)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Low protein diet (humans)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High protein diet (mice)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control diet (mice)
Number of subjects: 29
Study: 24193079

Group type: EXPERIMENTAL
Intervention: Depression Engagement Video (DEV)
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Tailored Interactive Multimedia Computer Program (IMCP)
Number of subjects: 925

Group type: COMPARATOR
Intervention: Control (Sleep Hygiene Video)
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Depressed Patients (PHQ-8 score at 12-week follow-up)
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Nondepressed Patients (Clinician-reported antidepressant prescribing)
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Nondepressed Patients (Patient-reported antidepressant recommendation)
Number of subjects: 925
Study: 20421153

Group type: COMPARATOR
Intervention: 68 Gy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 78 Gy
Number of subjects: 300
Study: 19644849

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg plus MTX
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg plus MTX
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg plus placebo
Number of subjects: 637

Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Combined golimumab groups (50 mg + MTX and 100 mg + MTX)
Number of subjects: 637
Study: 17605597

Group type: EXPERIMENTAL
Intervention: Nutrient-enriched post-discharge formula (PDF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard term formula (TF)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (PDF and TF)
Number of subjects: 20
Study: 14665448

Group type: EXPERIMENTAL
Intervention: Dexamethasone 2.0 mg orally
Number of subjects: 16
Study: 11703573

Group type: EXPERIMENTAL
Intervention: Interferon therapy (IFN)
Number of subjects: 62
Study: 9380826

Group type: EXPERIMENTAL
Intervention: Soft immobilization device supporting the lower legs and polycarbonate insert
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard treatment couch
Number of subjects: 61

Group type: COMPARATOR
Intervention: Table top stiffened using a 1 cm polycarbonate insert
Number of subjects: 61
Study: 7898001

Group type: EXPERIMENTAL
Intervention: Administration of antibiotics for treatment of the recurrence
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: biseptol + glucocorticoids
Number of subjects: 11
Study: 2954026

Group type: EXPERIMENTAL
Intervention: MaxEPA supplementation
Number of subjects: 39

Group type: COMPARATOR
Intervention: No DHA supplementation (Control)
Number of subjects: 39
Study: 31267277

Group type: EXPERIMENTAL
Intervention: Reflexology intervention (4 weekly sessions, 30-min protocol)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 256
Study: 28960520

Group type: EXPERIMENTAL
Intervention: 5-FU 0.5%/salicylic acid 10%
Number of subjects: 27

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 27
Study: 26972584

Group type: EXPERIMENTAL
Intervention: SB4
Number of subjects: 138

Group type: COMPARATOR
Intervention: EU‐ETN
Number of subjects: 138
Study: 25424947

Group type: EXPERIMENTAL
Intervention: A/H1N1 vaccine formulations with varying antigen quantity (3.75 µg to 30 µg of hemagglutinin) and MF59(®) adjuvant (none, half dose, or full dose)
Number of subjects: 2592

Group type: EXPERIMENTAL
Intervention: A single vaccine dose containing 3.75 µg of A/California/7/2009 (H1N1) antigen with MF59 adjuvant
Number of subjects: 2592
Study: 24360042

Group type: EXPERIMENTAL
Intervention: Modified balloon dilatation and traditional swallowing therapy (E-stim, Mendelsohn Maneuver, supraglottic swallowing) for 3 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional swallowing therapy for 3 weeks
Number of subjects: 30
Study: 21827440

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg (group SP2)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Propofol 1 mg/kg (group SP1)
Number of subjects: 104
Study: 18279736

Group type: EXPERIMENTAL
Intervention: On-treatment triglycerides (TG) <150 mg/dl
Number of subjects: 4162

Group type: EXPERIMENTAL
Intervention: Each 10 mg/dl decrement in on-treatment TG
Number of subjects: 4162

Group type: EXPERIMENTAL
Intervention: TG <150 mg/dl and LDL-C <70 mg/dl
Number of subjects: 4162

Group type: EXPERIMENTAL
Intervention: Low on-treatment TG, LDL-C, and C-reactive protein (<2 mg/l)
Number of subjects: 4162
Study: 16545135

Group type: EXPERIMENTAL
Intervention: Random gentamicin concentration measured 4-20 hours after administration
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nomogram validation in 39 further babies, median gestation 34 weeks (28-41)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Prematurity indicator (< or = 37 weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Preterm babies
Number of subjects: 50
Study: 15023597

Group type: EXPERIMENTAL
Intervention: High meat diet (HM) - 34% protein, 46% carbohydrate, 20% fat
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low meat diet (LM) - 17% protein, 64% carbohydrate, 20% fat
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High meat diet (HM) for subjects with high triglycerides (>1.5mmol/L)
Number of subjects: 100
Study: 10919421

Group type: EXPERIMENTAL
Intervention: Epidural infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 40
Study: 8706601

Group type: EXPERIMENTAL
Intervention: Colour-flow echocardiography
Number of subjects: 1115
Study: 1433454

Group type: EXPERIMENTAL
Intervention: Expressed breastmilk (EBM)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Milk formula
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Parenteral feeding
Number of subjects: 50
Study: 2987445

Group type: EXPERIMENTAL
Intervention: Learning style assessment (experimental group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cognitive style mapping assessment (control group)
Number of subjects: 60
Study: 31759770

Group type: EXPERIMENTAL
Intervention: Omegaven (fish oil) supplementation for 4 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Omegaven (fish oil) supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Smoflipid regimen
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lipoplus regimen
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LPS-stimulated production of IL-6
Number of subjects: 12
Study: 30387900

Group type: EXPERIMENTAL
Intervention: Combined femoral and common peroneal nerve blocks with 0.33% ropivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham blocks with saline
Number of subjects: 40
Study: 27871427

Group type: EXPERIMENTAL
Intervention: Increased admission glucose
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Hyperglycemia on admission
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 335
Study: 26982667

Group type: EXPERIMENTAL
Intervention: Dexamethasone + Pheniramine hydrogen maleate (8mg/2ml + 45.5/2ml)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (5 ml)
Number of subjects: 120
Study: 22018049

Group type: EXPERIMENTAL
Intervention: PS-SM (0.1% dairy fat)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PS-VFM (0.1% dairy fat plus 1.5% vegetable fat)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control SM
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PS-SM and PS-VFM
Number of subjects: 43
Study: 19707025

Group type: EXPERIMENTAL
Intervention: Enteral probiotics supplementation
Number of subjects: 1425

Group type: COMPARATOR
Intervention: Placebo or no treatment
Number of subjects: 1425
Study: 18073378

Group type: EXPERIMENTAL
Intervention: Anastrozole for 3 years
Number of subjects: 856

Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 856
Study: 16282845

Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion
Number of subjects: 36

Group type: COMPARATOR
Intervention: Naltrexone
Number of subjects: 36
Study: 12383143

Group type: EXPERIMENTAL
Intervention: Incontinence care and exercise intervention (provided every 2 hours from 8:00 a.m. to 4:00 p.m. 5 days a week)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 256
Study: 10514772

Group type: EXPERIMENTAL
Intervention: Anxiety influence on cognitive processes during exams
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiological symptoms perception
Number of subjects: 0
Study: 7564674

Group type: EXPERIMENTAL
Intervention: Azithromycin 20 mg/kg weekly (days 1, 8, and 15)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Tetracycline eye ointment (days 1-42)
Number of subjects: 226
Study: 1688482

Group type: EXPERIMENTAL
Intervention: 160 mg of sotalol administered twice daily
Number of subjects: 172

Group type: COMPARATOR
Intervention: 40 mg of propranolol administered 3 times daily
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 320 mg of sotalol administered twice daily
Number of subjects: 172

Group type: COMPARATOR
Intervention: 80 mg of propranolol administered 3 times daily
Number of subjects: 172
Study: 371742

Group type: EXPERIMENTAL
Intervention: Metronidazole and Thalazole
Number of subjects: 120

Group type: COMPARATOR
Intervention: Thalazole alone
Number of subjects: 120
Study: 31736337

Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Number of subjects: 2479

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 2479
Study: 30617697

Group type: EXPERIMENTAL
Intervention: Lunches served in CCs
Number of subjects: 61

Group type: COMPARATOR
Intervention: Saskatchewan centres
Number of subjects: 61

Group type: COMPARATOR
Intervention: French-speaking centres
Number of subjects: 61

Group type: COMPARATOR
Intervention: Rural and urban centres
Number of subjects: 61
Study: 26117466

Group type: EXPERIMENTAL
Intervention: 180 mg loading dose (LD) of ticagrelor
Number of subjects: 60

Group type: COMPARATOR
Intervention: 90 mg maintenance dose (MD) of ticagrelor
Number of subjects: 60
Study: 23229236

Group type: COMPARATOR
Intervention: Anesthetic blockage of the auriculotemporal nerve with injections of 1 ml of bupivacaine 0.5% without vasoconstrictor for 8 weeks (group 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Anesthetic blockage and physical therapy (massage and muscular stretching exercises) (group 2)
Number of subjects: 20
Study: 21451030

Group type: EXPERIMENTAL
Intervention: Vector average readout of direction signals accumulated over time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum likelihood readout of direction signals combined over space
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Population decoding model simulations
Number of subjects: 0
Study: 19351633

Group type: EXPERIMENTAL
Intervention: Plasma apelin concentration post-AMI
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Plasma apelin concentration at 24 weeks post-AMI
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation of baseline apelin with norepinephrine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NT-proBNP and norepinephrine correlation with adverse ventricular function
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (38 subjects with no cardiac history)
Number of subjects: 100
Study: 16690431

Group type: EXPERIMENTAL
Intervention: Iodine (131I) metuximab injection (27.75 MBq/kg)
Number of subjects: 134
Study: 15066459

Group type: EXPERIMENTAL
Intervention: 50 mg of sildenafil citrate (VIAGRA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 8‐Bromo‐cGMP (20 microM; 60 minutes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11446841

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 9730139

Group type: EXPERIMENTAL
Intervention: Pvu II +/+ genotype in low-HDL/high-TG children
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Pvu II+ allele of the LPL gene
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: LPL(Arita) mutation
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: LPL Asn291Ser and Gly188Glu variants
Number of subjects: 308
Study: 8014692

Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Erythropoietin plus recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Packed erythrocyte transfusions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Erythropoietin plus GM-CSF
Number of subjects: 16
Study: 2567579

Group type: EXPERIMENTAL
Intervention: H1 receptor antagonist, levocabastine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: H2 receptor antagonist, ranitidine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: H1 and/or H2 antagonists
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 5335457

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31425283

Group type: EXPERIMENTAL
Intervention: Naturalistic coaching behavior during surgery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Self-identified goals
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Collaborative analysis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Coaching principles
Number of subjects: 20
Study: 30695071

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study: 27798730

Group type: EXPERIMENTAL
Intervention: Apatinib treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26295507

Group type: EXPERIMENTAL
Intervention: Hydrocortisone cream
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Placebo cream
Number of subjects: 27

Group type: COMPARATOR
Intervention: No cream application (Control)
Number of subjects: 27
Study: 23613569

Group type: EXPERIMENTAL
Intervention: SFC 50/250 µg, twice daily
Number of subjects: 1543

Group type: COMPARATOR
Intervention: SAL 50 µg, twice daily
Number of subjects: 1543
Study: 22065897

Group type: EXPERIMENTAL
Intervention: GC501
Number of subjects: 283
Study: 19380124

Group type: EXPERIMENTAL
Intervention: History-indicated cervical cerclage
Number of subjects: 247

Group type: COMPARATOR
Intervention: Ultrasound-indicated cervical cerclage
Number of subjects: 247
Study: 16501262

Group type: EXPERIMENTAL
Intervention: Web-based teaching on two of the four urologic topics
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Web-based teaching
Number of subjects: 351

Group type: COMPARATOR
Intervention: No Web-based teaching
Number of subjects: 351
Study: 15181058

Group type: EXPERIMENTAL
Intervention: Combined hormone therapy (CHT) - continuous conjugated equine estrogen/cyclical micronized progesterone for 3 months
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10886121

Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Yohimbine 22 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg + Yohimbine 22 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11480052

Group type: EXPERIMENTAL
Intervention: Koukangning gargle (experimental group, 59 patients)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Dobell's solution (control group 1, 29 patients)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Koutai solution (control group 2, 30 patients)
Number of subjects: 118
Study: 8513841

Group type: EXPERIMENTAL
Intervention: Low dose hamamelis PC-cream
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 1% cream
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hamamelis cream (without PC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chamomile cream
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hamamelis PC-cream
Number of subjects: 24

Group type: COMPARATOR
Intervention: Untreated control area
Number of subjects: 24
Study: 2948431

Group type: EXPERIMENTAL
Intervention: High fat diet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fasting condition
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 18
Study: 31808686

Group type: EXPERIMENTAL
Intervention: MHBAs (35 mg/day)
Number of subjects: 60
Study: 29629845

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 28290272

Group type: EXPERIMENTAL
Intervention: SCP beverage (333 mg SCP) daily for 6 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control beverage (0 mg SCP)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: SCP beverage (333 mg SCP)
Number of subjects: 41
Study: 25504868

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation
Number of subjects: 51
Study: 23172972

Group type: EXPERIMENTAL
Intervention: Resistance exercise (weight lifting)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (running at 60% of Vo(2max))
Number of subjects: 12

Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 12
Study: 21240015

Group type: EXPERIMENTAL
Intervention: Calcium 75 mg · kg⁻¹ · day⁻¹ (high dose)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Calcium 45 mg · kg⁻¹ · day⁻¹ (low dose)
Number of subjects: 86
Study: 18325386

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg orally twice daily
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 105
Study: 16443339

Group type: EXPERIMENTAL
Intervention: Oral fat tolerance test (OFTT) in menopausal women with MetS
Number of subjects: 33
Study: 12900303

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 45
Study: 10096976

Group type: EXPERIMENTAL
Intervention: Heparin-coated cardiopulmonary bypass
Number of subjects: 156

Group type: COMPARATOR
Intervention: Uncoated cardiopulmonary bypass
Number of subjects: 156
Study: 8905004

Group type: EXPERIMENTAL
Intervention: Formoterol inhaled via dry-powder (DP) capsule inhaler
Number of subjects: 12

Group type: COMPARATOR
Intervention: Formoterol inhaled via pressurized metered-dose inhaler (pMDI)
Number of subjects: 12
Study: 1910651

Group type: EXPERIMENTAL
Intervention: Weekly (intensive) neurodevelopmental therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Monthly (basic) neurodevelopmental therapy
Number of subjects: 29
Study: 7082780

Group type: EXPERIMENTAL
Intervention: New enteric-coated phenylbutazone (100 mg and 200 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Commercially available Butacote
Number of subjects: 8